|Day Low/High||0.23 / 0.27|
|52 Wk Low/High||0.06 / 0.34|
*** Provides Funding to Advance Development of Products Utilizing LIMITx™ Technology ***
*** Peak blood levels of abused LIMITx doses can be reduced up to 65% ***
Expands Commercialization of Acura's Methamphetamine-Resistant Pseudoephedrine Products
Roth Capital Engaged to Assist in the Process
Stocks may go on another wild ride today.
Acura Pharmaceuticals (ACUR) shares are up over 30% after the company entered into a licensing and development deal with Bayer Healthcare (BAYRY) for its IMPEDE technology.
TheStreet highlights 3 stocks that pushed the Drugs industry
Acura Pharmaceuticals (Nasdaq:ACUR) has been downgraded by TheStreet Ratings from from a hold to sell.
Upgrades: ADEP, ALLB, ATAX, ENG, FULL, MBT, RSTI Downgrades: ACUR, BEAT, BIG, BWINB, CCJ, CHS, FAC, NAVI, PAR Initiations: VPCO Read on to get TheStreet Quant Ratings' detailed report:
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
These stocks look ready to break out and trade higher from current levels.
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Acura Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.